PatientsVille.com Logo

PatientsVille

Erythrocin Side Effects

Common Erythrocin Side Effects


The most commonly reported Erythrocin side effects (click to view or check a box to report):

Pyrexia (7)
Vision Blurred (5)
Rash (5)
Nausea (5)
Abdominal Pain (5)
Chest Pain (5)
Condition Aggravated (4)
Renal Failure Acute (4)
Eyelid Oedema (4)
Diarrhoea (3)
Deafness (3)
Alanine Aminotransferase Increased (3)
Dyspnoea (3)
Platelet Count Decreased (3)
Eye Irritation (3)
Pancreatitis Acute (3)
Multi-organ Failure (3)
Lip Haemorrhage (2)
Muscle Twitching (2)
Malaise (2)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Erythrocin Side Effects Reported to FDA

The following Erythrocin reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Erythrocin on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Leukocytosis
This is a report of a 64-year-old male patient (weight: NA) from FR, suffering from the following symptoms/conditions: NA, who was treated with Erythrocine /00020901/ (erythrocine) (not Specified) (dosage: (1 G 1x/3 Days Intravenous (not Otherwise Specified)), start time: Sep 19, 2009), combined with:
  • Cordarone (cordarone - Amiodarone) (not Specified) ((df Intravenous (not Otherwise Specified)))
  • Cefotaxime Sodium (cefotaxime Sodium) ((df Intravenous (not Otherwise Specified)))
  • Lasilix /00032601/ (lasilix - Furosemide) (not Specified) ((df Intravenous (not Otherwise Specified)))
  • Tazocilline (tazocilline - Tazobactam) (not Specified) ((df))
  • Cefotaxime
  • Cefepime
and developed a serious reaction and side effect(s). The consumer presented with:
  • Leukocytosis
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Erythrocine /00020901/ (erythrocine) (not Specified) treatment in male patients, resulting in leukocytosis side effect. The patient was hospitalized.

Interstitial Lung Disease, Aspartate Aminotransferase Increased, Alanine Aminotransferase Increased, Gamma-glutamyltransferase Decreased
This report suggests a potential Erythrocin Interstitial Lung Disease, Aspartate Aminotransferase Increased, Alanine Aminotransferase Increased, Gamma-glutamyltransferase Decreased side effect(s) that can have serious consequences. A 97-year-old male patient (weight: NA) from JP was diagnosed with the following symptoms/conditions: NA and used Erythrocin (dosage: NA) starting Oct 31, 2013. Soon after starting Erythrocin the patient began experiencing various side effects, including:
  • Interstitial Lung Disease
  • Aspartate Aminotransferase Increased
  • Alanine Aminotransferase Increased
  • Gamma-glutamyltransferase Decreased
Drugs used concurrently:
  • Bayaspirin
  • Ebastel
  • Theodur
  • Takepron
  • Carbocisteine Lysine
  • Ambroxol Hydrochloride
  • Levothyroxine Sodium
  • Sennoside /00571901/
Although Erythrocin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as interstitial lung disease, may still occur.

Injection Site Vasculitis
This Injection Site Vasculitis problem was reported by a pharmacist from JP. A 81-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: brain abscess. On Jun 15, 2013 this consumer started treatment with Erythrocin Lactobionate (dosage: [1 Vial Dissolved W/ 10ml Water For Injection,diluted With 100 Ml Saline, Administered Over 2 Hours). The following drugs were being taken at the same time:
  • Meropenem Trihydrate
When commencing Erythrocin Lactobionate, the patient experienced the following unwanted symptoms/side effects:
  • Injection Site Vasculitis
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as injection site vasculitis, may become evident only after a product is in use by the general population.

Deafness
This is a report of a female patient (weight: NA) from JP. The patient developed the following symptoms/conditions: NA and was treated with Erythrocin (dosage: NA) starting 201208. Concurrently used drugs:
  • Biological Preparations
  • Cimetidine
Soon after that, the consumer experienced the following side effects:
  • Deafness
This opens a possibility that Erythrocin treatment could cause the above reactions, including deafness, and some female subjects may be more susceptible.


Thrombocytopenia
A 65-year-old female patient (weight: NA) from JP with the following symptoms/conditions: postoperative wound infection started Erythrocin treatment (dosage: NA) on Jan 27, 2013. Soon after starting Erythrocin treatment, the subject experienced various side effects, including:
  • Thrombocytopenia
Concurrently used drugs:
  • Targocid
  • Rifampicin
  • Warfarin Potassium
  • Aspirin
  • Magnesium Oxide
The patient was hospitalized. This finding indicates that some female patients could be more vulnerable to Erythrocin.

Pulmonary Sarcoidosis, Aspartate Aminotransferase Increased, Alanine Aminotransferase Increased, Lymphocyte Stimulation Test Positive, Granuloma, Necrosis, Eczema
A 26-year-old female patient from JP (weight: NA) experienced symptoms, such as: diffuse panbronchiolitis and was treated with Erythrocin(dosage: (df)). The treatment was initiated on 2010. After that a consumer reported the following side effect(s):
  • Pulmonary Sarcoidosis
  • Aspartate Aminotransferase Increased
  • Alanine Aminotransferase Increased
  • Lymphocyte Stimulation Test Positive
  • Granuloma
  • Necrosis
  • Eczema
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Erythrocin efficacy:
  • Klaricid ((df))
  • Clarithromycin (clarithromycin) ((df))
  • Loxoprofen Sodium ((df))
  • Loxonin
The patient was hospitalized.

Hepatitis, Renal Failure Acute, Duodenal Fistula, Toxic Skin Eruption
In this report, Erythrocin was administered for the following condition: antibiotic prophylaxis.A 77-year-old male consumer from FR (weight: NA) started Erythrocin treatment (dosage: NA) on Jul 13, 2012.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Hepatitis
  • Renal Failure Acute
  • Duodenal Fistula
  • Toxic Skin Eruption
A possible interaction with other drugs could have contributed to this reaction:
  • Tazocilline
  • Tienam
  • Tienam
  • Amikacin
  • Vancomycine Merck
The patient was hospitalized.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Erythrocin treatment could be related to the listed above side effect(s).

Erythema, Hepatitis, Renal Failure Acute, Pyrexia, Eosinophilia
This is a report of the following Erythrocin side effect(s):
  • Erythema
  • Hepatitis
  • Renal Failure Acute
  • Pyrexia
  • Eosinophilia
A 77-year-old male patient from FR (weight: NA) presented with the following condition: antibiotic prophylaxis and received a treatment with Erythrocin (dosage: NA) starting: Jul 13, 2012.The following concurrently used drugs could have generated interactions:
  • Tazocilline
  • Tienam
  • Amikacine Merck
  • Vancomycine Merck
The patient was hospitalized.This report suggests that a Erythrocin treatment could be associated with the listed above side effect(s).

Neutropenia, Lymphopenia
This Erythrocin report was submitted by a 69-year-old female consumer from FR (weight: NA). The patient was diagnosed with: NA and Erythrocin was administered (dosage: NA) starting: Sep 18, 2012. The consumer developed a set of symptoms:
  • Neutropenia
  • Lymphopenia
Other drugs used simultaneously:
  • Rocephine
  • Ofloxacine
  • Glucophage
  • Daonil
  • Fractal
The patient was hospitalized.Those unexpected symptoms could be linked to a Erythrocin treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Hepatocellular Injury, Hepatomegaly, Liver Injury, Pyrexia, Jaundice
This is a report of a possible correlation between Erythrocine use and the following symptoms/side effect(s):
  • Hepatocellular Injury
  • Hepatomegaly
  • Liver Injury
  • Pyrexia
  • Jaundice
which could contribute to an assessment of Erythrocine risk profile.A 11-year-old female consumer from FR (weight: NA) was suffering from pertussis and was treated with Erythrocine (dosage: (df Oral)) starting Aug 24, 2012.Other concurrent medications: NA.The patient was hospitalized.

Cholestasis, Gamma-glutamyltransferase Increased, Alanine Aminotransferase Increased, Blood Alkaline Phosphatase Increased
A 53-year-old male patient from FR (weight: NA) presented with the following symptoms: gastrointestinal motility disorder and after a treatment with Erythrocine (dosage: NA) experienced the following side effect(s):
  • Cholestasis
  • Gamma-glutamyltransferase Increased
  • Alanine Aminotransferase Increased
  • Blood Alkaline Phosphatase Increased
The treatment was started on Jul 03, 2012. Erythrocine was used in combination with the following drugs:
  • Inexium
  • Vitamin B1
  • Imovane
  • Oliclinomel
This report could alert potential Erythrocine consumers.

Bradycardia, Blood Pressure Decreased, Epilepsy
In this report, a 7-year-old female patient from JP (weight: NA) was affected by a possible Erythrocin W (erythromycin Ethylsuccinate) side effect.The patient was diagnosed with NA. After a treatment with Erythrocin W (erythromycin Ethylsuccinate) (dosage: NA, start date: Apr 09, 2012), the patient experienced the following side effect(s):
  • Bradycardia
  • Blood Pressure Decreased
  • Epilepsy
The following simultaneously used drugs could have led to this reaction:
  • Depakene (valproic Acid)
  • Procaterol (procaterol)
  • Theophylline (theophylline)
  • Lioresal (baclofen)
  • Etizolam (etizolam)
  • Eurodin (dihydroergocristine Mesilate)
  • Pantethine (pantethine)
  • Qvar (beclometasone Dipropionate)
The findings here stress that side effects should be taken into consideration when evaluating a Erythrocin W (erythromycin Ethylsuccinate) treatment.

Condition Aggravated, Eyelid Irritation
This is a report of a 91-year-old female patient from UNITED STATES (weight: NA), who used Erythrocin 1% (dosage: NA) for a treatment of eyelid infection. After starting a treatment on Feb 17, 2012, the patient experienced the following side effect(s):
  • Condition Aggravated
  • Eyelid Irritation
The following drugs could possibly have interacted with the Erythrocin 1% treatment
  • Alrex
  • Multivitamin
Taken together, these observations suggest that a Erythrocin 1% treatment could be related to side effect(s), such as Condition Aggravated, Eyelid Irritation.

Interstitial Lung Disease
This interstitial lung disease side effect was reported by a physician from JAPAN. A 72-year-old male patient (weight:NA) experienced the following symptoms/conditions: NA. The patient was prescribed Erythrocin Lactobionate (dosage: NA), which was started on May 11, 2009. Concurrently used drugs:
  • Levoleucovorin Calcium
  • Levoleucovorin Calcium
  • Warfarin Sodium
  • Magmitt
  • Minocycline Hcl
  • Erbitux
  • Fluorouracil
  • Fluorouracil
When starting to take Erythrocin Lactobionate the consumer reported the following symptoms:
  • Interstitial Lung Disease
The patient was hospitalized. These side effects may potentially be related to Erythrocin Lactobionate.

Pain, Vein Wall Hypertrophy, Anxiety, Anhedonia, Deep Vein Thrombosis, Deformity
This is a Erythrocin Lactobionate side effect report of a 19-year-old female patient (weight:NA) from CHINA, suffering from the following symptoms/conditions: NA, who was treated with Erythrocin Lactobionate (dosage:Unk, start time: Jan 01, 2004), combined with:
  • Zyrtec
  • Diosmin (25 Mg, Bid)
  • Yaz (Unk)
  • Zithromax
  • Differin (0.1 %, Prn)
  • Synthroid (Unk)
, and developed a serious reaction and a pain side effect. The patient presented with:
  • Pain
  • Vein Wall Hypertrophy
  • Anxiety
  • Anhedonia
  • Deep Vein Thrombosis
  • Deformity
which developed after the beginning of treatment. The patient was hospitalized. This side effect report can indicate a possible existence of increased vulnerability to Erythrocin Lactobionate treatment in female patients suffering from NA, resulting in pain.

Deafness
This report suggests a potential Erythrocin Lactobionate deafness side effect(s) that can have serious consequences. A female patient from JAPAN (weight:NA) was diagnosed with the following health condition(s): mediastinal abscess,lung abscess,sepsis and used Erythrocin Lactobionate (dosage: NA) starting Nov 02, 2010. Soon after starting Erythrocin Lactobionate the patient began experiencing various side effects, including:
  • Deafness
Drugs used concurrently:
  • Amikacin Sulfate
  • Amikacin Sulfate
  • Amikacin Sulfate
  • Imipenem And Cilastatin Sodium
  • Imipenem And Cilastatin Sodium
  • Carbimazol
Although Erythrocin Lactobionate demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as deafness, may still occur.

Disseminated Intravascular Coagulation, Pancreatitis Acute
This disseminated intravascular coagulation problem was reported by a health professional from JAPAN. A 6-year-old female patient (weight: NA) was diagnosed with the following medical condition(s): NA.On NS a consumer started treatment with Erythrocin (dosage: (1 Gm) Oral)). The following drugs/medications were being taken at the same time: NA. When commencing Erythrocin, the patient experienced the following unwanted symptoms /side effects:
  • Disseminated Intravascular Coagulation
  • Pancreatitis Acute
Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as disseminated intravascular coagulation, may become evident only after a product is in use by the general population.

Embolic Stroke, Cardiac Failure Congestive, Activated Partial Thromboplastin Time Prolonged
This is a Erythrocin Lactobionate side effect report of a male patient (weight: NA) from JAPAN. The patient developed the following symptoms/conditions: bronchiectasis and was treated with Erythrocin Lactobionate (dosage: 600 Mg) starting Jul 13, 2011. Concurrently used drugs:
  • Cleanal (1200 Mg)
  • Pradaxa (220 Mg)
  • Zolpidem
  • Gamofa (40 Mg)
Soon after that, the consumer experienced the following of symptoms:
  • Embolic Stroke
  • Cardiac Failure Congestive
  • Activated Partial Thromboplastin Time Prolonged
The patient was hospitalized. This opens a possibility that Erythrocin Lactobionate could cause embolic stroke and that some male patients may be more susceptible.

Diplopia, Vision Blurred
A 62-year-old male patient (weight: NA) from UNITED STATES with the following symptoms: eyelid infection started Erythrocin 1% treatment (dosage: NA) on Jul 19, 2010. Soon after starting Erythrocin 1% treatment, the consumer experienced several side effects, including:
  • Diplopia
  • Vision Blurred
. Concurrently used drugs: NA. This finding indicates that some patients can be more vulnerable to developing Erythrocin 1% side effects, such as diplopia.

Depressed Level Of Consciousness, Arrhythmia, Chest Pain, Cor Pulmonale, Ventricular Tachycardia, Respiratory Arrest
This depressed level of consciousness side effect was reported by a health professional from JAPAN. A female patient (weight:NA) experienced the following symptoms/conditions: bronchiolitis.The patient was prescribed Erythrocin (dosage: 600 Mg, (200 , 3 In 1 D) Oral), which was started on Jun 30, 2006. Concurrently used drugs:
  • Pimobendam
  • Theophylline
  • Tiotropium Bromide Monohdrate
  • Dospyramide
  • Furosemide
  • Rabeprazole Sodium
  • Ursodiol
  • Clarithromycin (200 Mg, (1 In 1 D) Oral, (800 Mg, 800mg (400 Mg, 2 In 1 D) Oral)
.When starting to take Erythrocin the consumer reported symptoms, such as:
  • Depressed Level Of Consciousness
  • Arrhythmia
  • Chest Pain
  • Cor Pulmonale
  • Ventricular Tachycardia
  • Respiratory Arrest
These side effects may potentially be related to Erythrocin.

Hypoglycaemia, Renal Failure Acute, Hyperkalaemia, Pneumocystis Jiroveci Pneumonia, Altered State Of Consciousness
This is a report of a 60-year-old male patient (weight: NA) from JAPAN, suffering from the following symptoms/conditions: NA, who was treated with Erythrocin Lactobionate (dosage: NA, start time: Jan 01, 2011), combined with:
  • Pyridoxal Phosphate
  • Fluticasone Propionate
  • Januvia
  • Isoniazid
  • Ganciclovir
  • Pentamidine Isethionate
  • Hokunalin
  • Amaryl
and developed a serious reaction and side effect(s). The consumer presented with:
  • Hypoglycaemia
  • Renal Failure Acute
  • Hyperkalaemia
  • Pneumocystis Jiroveci Pneumonia
  • Altered State Of Consciousness
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Erythrocin Lactobionate treatment in male patients, resulting in hypoglycaemia side effect. The patient was hospitalized.

Oculomucocutaneous Syndrome, Stevens-johnson Syndrome
This report suggests a potential Erythrocin Oculomucocutaneous Syndrome, Stevens-johnson Syndrome side effect(s) that can have serious consequences. A 30-year-old female patient (weight: NA) from JAPAN was diagnosed with the following symptoms/conditions: NA and used Erythrocin (dosage: (200 Mg)) starting Jan 01, 2009. Soon after starting Erythrocin the patient began experiencing various side effects, including:
  • Oculomucocutaneous Syndrome
  • Stevens-johnson Syndrome
Drugs used concurrently: NA. Although Erythrocin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as oculomucocutaneous syndrome, may still occur.

Platelet Count Decreased
This Platelet Count Decreased problem was reported by a pharmacist from JAPAN. A 81-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Erythrocin Lactobionate (dosage: 500 Mg, 2x/day). The following drugs were being taken at the same time:
  • Solu-medrol (500 Mg, 2x/day)
  • Amlodipine (5 Mg, 1x/day)
  • Lasix (20 Mg, 1x/day)
  • Unasyn (1.5 Mg, 2x/day)
  • Glyburide (1.25 Mg, 1x/day)
  • Paxil (Unk)
When commencing Erythrocin Lactobionate, the patient experienced the following unwanted symptoms/side effects:
  • Platelet Count Decreased
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as platelet count decreased, may become evident only after a product is in use by the general population.

Nausea
This is a report of a female patient (weight: NA) from UNITED STATES. The patient developed the following symptoms/conditions: NA and was treated with Erythrocin Lactobionate (dosage: NA) starting Apr 15, 2010. Concurrently used drugs:
  • Synthroid
  • Crestor
  • Mvt
  • Calcium
  • Vitamin D
  • Fish Oil
Soon after that, the consumer experienced the following side effects:
  • Nausea
This opens a possibility that Erythrocin Lactobionate treatment could cause the above reactions, including nausea, and some female subjects may be more susceptible.

Dyspnoea
A 45-year-old male patient (weight: NA) from UNITED KINGDOM with the following symptoms/conditions: NA started Erythrocin Es 500 Mg Tablets treatment (dosage: NA) on Sep 30, 2010. Soon after starting Erythrocin Es 500 Mg Tablets treatment, the subject experienced various side effects, including:
  • Dyspnoea
Concurrently used drugs: NA. This finding indicates that some male patients could be more vulnerable to Erythrocin Es 500 Mg Tablets.

1 of 4 



Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Erythrocin Side Effects

    Did You Have a Erythrocin Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Erythrocin for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Erythrocin Safety Alerts, Active Ingredients, Usage Information

    NDC0074-6316
    TypeHUMAN PRESCRIPTION DRUG
    Proprietary NameErythrocin Stearate
    NameErythromycin Stearate
    Dosage FormTABLET, FILM COATED
    RouteORAL
    On market since19640624
    LabelerAbbVie Inc.
    Active Ingredient(s)ERYTHROMYCIN STEARATE
    Strength(s)500
    Unit(s)mg/1
    Pharma ClassDecreased Sebaceous Gland Activity [PE],Macrolide [EPC],Macrolide Antimicrobial [EPC],Macrolides [Ch

    More About Erythrocin

    Side Effects reported to FDA: 88

    Erythrocin safety alerts: No

    Reported deaths: 9

    Reported hospitalizations: 20

    Latest Erythrocin clinical trials

    Erythrocin Reviews

    No reviews, be a first to report a side effect via side effect reporting form